THE CFO of drug discovery and development company e-Therapeutics has resigned, with a former adviser stepping into the role.
Dr Daniel Elger has left the listed UK pharmacology business with immediate effect. In a stock exchange statement earlier this morning, e-Therapeutics announced that its financial controller will hold the interim FD role, however, it then followed up an hour later with another statement announcing Steve Medlicott as FD.
Medlicott, a PwC-trained chartered accountant, advised the company during its fundraising in 2013. He has served in a range of business development and sell-side roles, with Peel Hunt, N+1 Singer, Altium Capital and Williams de Broe. He has also served as director of finance at Waste2Tricity.
Professor Malcolm Young, chief executive of e-Therapeutics, said: “We are excited to welcome Steve to the company as our finance director. He has unsurpassed knowledge and understanding of the financial markets and of e-Therapeutics, having supported us to raise funds in 2013. His capabilities and experience will be very valuable to us.”
The Oxford- and Newcastle-based biotech business recently provided encouraging news around its anti-cancer drug trials, which saw analyst Edison Group restate its positive rating on its shares.
Big Data software company WANdisco has appointed Erik Miller as chief financial officer and with immediate effect
Join Financial Director, Oracle and a host of ‘Fast Data’ experts to discover how financial professionals can help create a Fast Data business
What can you do to ensure your employees know the company policy and stick to it? Hear from other CFOs and experts in our free-to-view video
The finance chief of the Daily Mail has been recruited by Rolls-Royce after a management shake-up at the engineering group has resulted in the departure of its chief financial officer